NASDAQ$NVCR
Novocure Ltd · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported revenue growth and financial strength, clinical pipeline developments and the company’s response to COVID-19.
Novocure reported a strong quarter with $102 million in net revenues, $4 million in net income, and $331 million cash on hand. Net revenues increased by 39% compared to the first quarter 2019.
- Net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019.
- Gross profit of $77.3 million, a 45% increase compared to Q1 2019.
- Net income of $4.0 million compared to a net loss of $12.2 million for the same period in 2019.
- Cash, cash equivalents and short-term investments at end of period $331.3 million, a 29% increase compared to Q1 2019.
Headline financials
Revenue & EPS history
Novocure · Revenue · Quarterly
$102M
Forward guidance
Novocure continues to advance its clinical milestones with data readouts expected over the next several years.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-0.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+2.6%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+27.5%
Q1 2026
Best reaction
-34.3%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +27.5% | +33.1% | +42.8% | |
| Q4 2025 | -7.9% | -11.3% | -26.8% | |
| Q3 2025 | -4.7% | -11.0% | -5.0% | |
| Q2 2025 | -0.3% | +3.9% | +4.6% | |
| Q1 2025 | +4.4% | +2.9% | +4.3% | |
| Q4 2024 | -12.4% | -17.2% | -14.1% | |
| Q3 2024 | -10.1% | -1.8% | +18.7% | |
| Q2 2024 | +1.2% | +24.2% | -4.1% | |
| Q1 2024 | +16.0% | +21.9% | +72.8% | |
| Q4 2023 | -2.6% | +4.4% | -15.4% | |
| Q3 2023 | -10.2% | -5.5% | -11.4% | |
| Q2 2023 | -17.4% | -19.1% | -26.2% | |
| Q1 2023 | +3.5% | +6.2% | +20.6% | |
| Q4 2022 | -6.1% | -6.1% | -30.3% | |
| Q3 2022 | +3.5% | +8.1% | +10.8% | |
| Q2 2022 | -8.1% | -5.1% | +11.9% | |
| Q1 2022 | -0.5% | +8.9% | +9.1% | |
| Q4 2021 | +10.1% | +10.5% | +9.8% | |
| Q3 2021 | -7.4% | -2.8% | -12.4% | |
| Q2 2021 | -15.3% | -18.0% | -25.9% | |
| Q1 2021 | -0.7% | -4.0% | -0.7% | |
| Q4 2020 | -13.9% | -11.6% | -28.1% | |
| Q3 2020 | +5.8% | -1.4% | +9.9% | |
| Q2 2020 | +11.5% | +14.9% | +20.6% | |
| Q1 2020 | -17.8% | -12.8% | -8.3% | |
| Q4 2019 | -8.4% | -12.7% | -17.6% | |
| Q3 2019 | +1.5% | +4.3% | +24.1% | |
| Q2 2019 | +11.2% | +17.3% | +30.3% | |
| Q1 2019 | +13.0% | +10.0% | +22.7% | |
| Q4 2018 | +4.0% | -2.5% | -10.8% | |
| Q3 2018 | -23.6% | -22.9% | -29.6% | |
| Q2 2018 | -6.7% | -9.2% | +6.8% | |
| Q1 2018 | +11.2% | +14.3% | +25.7% | |
| Q4 2017 | -10.4% | -1.9% | +1.9% | |
| Q3 2017 | +7.5% | +19.3% | +4.7% | |
| Q2 2017 | +4.3% | +2.3% | +2.1% | |
| Q1 2017 | +3.2% | +8.2% | +16.4% | |
| Q4 2016 | -3.5% | +6.3% | -1.4% | |
| Q3 2016 | +13.4% | +21.8% | +34.5% | |
| Q2 2016 | -34.3% | -31.6% | -31.6% | |
| Q1 2016 | +2.3% | — | — | |
| Q4 2015 | +24.7% | — | — | |
| Q3 2015 | +22.3% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro